Patents Issued in January 16, 2024
  • Patent number: 11872198
    Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: January 16, 2024
    Assignee: Purdue Research Foundation
    Inventors: Kee-Hong Kim, Yuyan Zhu
  • Patent number: 11872199
    Abstract: A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.
    Type: Grant
    Filed: January 9, 2023
    Date of Patent: January 16, 2024
    Assignee: SMARTECH TOPICAL, INC.
    Inventor: Thomas Hnat
  • Patent number: 11872200
    Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: January 16, 2024
    Assignee: The Regents of the University of California
    Inventors: Daniel L Kaufman, Jide Tian
  • Patent number: 11872201
    Abstract: There is provided a vegetable-based lipid composition comprising very high levels of DHA, together with at least one other long-chain polyunsaturated fatty acid (typically as fatty acid esters). The composition typically contains low levels of EPA and palmitic acid. The composition is obtainable from a single source by conventional processing methods, and has improved stability properties.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: January 16, 2024
    Assignee: Nuseed Nutritional US Inc.
    Inventor: Stuart Littler
  • Patent number: 11872202
    Abstract: A pleuromutilin cinnamic acid ester compound with activities against antibiotic-resistant infections having the following formula (I) R1, R2, R3, R4 and R5 are independently hydrogen, halogen, nitro, cyano, methoxy, trifluoromethyl, benzyloxy, aryl or dimethylamino.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: January 16, 2024
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Xiuding Yang, Liang Xin, Juan Xia, Yuqing Zhao, Jie Zhang, Lei Tian, Jingyi Li, Shaojun Zhang, Qianqian Zhao
  • Patent number: 11872203
    Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
    Type: Grant
    Filed: May 24, 2023
    Date of Patent: January 16, 2024
    Assignee: Axsome Malta Ltd.
    Inventor: Herriot Tabuteau
  • Patent number: 11872204
    Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
    Type: Grant
    Filed: May 24, 2023
    Date of Patent: January 16, 2024
    Assignee: Axsome Malta Ltd.
    Inventor: Herriot Tabuteau
  • Patent number: 11872205
    Abstract: Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: January 16, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gerald F. Swiss, Jesse Crowne, Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11872206
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 16, 2024
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11872207
    Abstract: The present application relates to methods of using compounds of Formulae (I) and (II): for treatment of various cancers. The application further relates to pharmaceutical compositions and uses comprising the compounds of the application.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: January 16, 2024
    Assignee: MCMASTER UNIVERSITY
    Inventors: Katarzyna Jerzak, Sukhbinder Dhesy-Thind, Anita Bane, Jessica Cockburn, John Hassell
  • Patent number: 11872208
    Abstract: The present invention relates to a veterinary or pharmaceutical composition comprising: (i) about 1-65% w/v of a pyrethroid, or a salt thereof, (ii) a macrocyclic lactone, or a salt thereof, (iii) at least one alkalizing agent, (iv) at least one non aqueous solvent, wherein the pH of the composition is comprised between about 6.5 and 8.5, when measured by adding 25% of water to an aliquot of said composition. The invention further relates to the use of such composition for preventing and/or treating parasites infestations.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: January 16, 2024
    Assignee: CEVA SANTE ANIMALE
    Inventors: Florence Guimberteau, Sandrine Lacoste, Romain Delcombel, Hamadi Karembe
  • Patent number: 11872209
    Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: January 16, 2024
    Assignee: Zydus Lifesciences Limited
    Inventors: Mukul R. Jain, Deven V. Parmar, Suresh Giri, Binu Philip, Pankaj Patel
  • Patent number: 11872210
    Abstract: Disclosed herein is a method of administering to a patient in need thereof a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound to treat or prevent a disease or condition influenced by the activity of one or more extracellular thiol isomerases (e.g. protein disulfide isomerase, ERp5, ERp57, ERp72 and thioredoxin). The disease or condition includes arterial thrombosis, venous thrombosis, a thrombotic disease, a cancer, an infectious disease, a viral disease, an immune disorder, inflammation, a neurologic disease, and a neurodegenerative disorder.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 16, 2024
    Assignee: WESTERN NEW ENGLAND UNIVERSITY
    Inventors: Daniel Kennedy, Jonathan Gibbins, Lisa-Marie Holbrook
  • Patent number: 11872211
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: January 16, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 11872212
    Abstract: The invention provides non-centrosymmetric organic crystals which show exceptional self-healing properties. More particularly, the present invention provides non-centrosymmetric substituted imidazole and Dialkyl 4,4?-methylenebis(azanediyl)dibenzoate Crystals and a process for preparation thereof. These highly crystalline materials, when broken into pieces, can self-propel and re-join in the blink of an eye and repair themselves so precisely that they become indistinguishable from the undisturbed materials.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 16, 2024
    Assignee: Indian Institute of Science Education and Research (IISER) Kolkata
    Inventors: Chilla Malla Reddy, Surojit Bhunia, Rituparno Chowdhury, Ishita Ghosh
  • Patent number: 11872213
    Abstract: Described herein are formulations including pharmaceutical agents comprising ester and/or lactone ring structures, and methods of using the same. The invention is also directed to a method and ophthalmic pharmaceutical compositions including solution and semisolid dosage forms (i.e. ophthalmic creams, gels, lotions, serums, and/or ointments) of treating a patient with various ocular diseases including presbyopia and dry eyes. The method comprising instructing a patient to apply one strip of the ophthalmic composition to the eyelids that includes pilocarpine or other active pharmaceutical ingredients containing ester and/or lactone ring structures with and without the buffering system.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: January 16, 2024
    Assignee: Glaukos Corporation
    Inventors: Xiaojun Michael Liu, James Jane-Guo Shiah, Gabriella Szekely
  • Patent number: 11872214
    Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: January 16, 2024
    Assignee: Eagle Pharmaceuticals, Inc.
    Inventors: Nagesh R. Palepu, Philip Christopher Buxton
  • Patent number: 11872215
    Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 16, 2024
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Geert-Jan Boons
  • Patent number: 11872216
    Abstract: The present invention relates to a pharmaceutical formulation in powder form comprising amoxicillin, cineole and a pharmaceutically acceptable oil. The present formulation may also comprise clavulanic acid. It is intended for oral administration, preferably after suspension in an aqueous solvent. The present invention also relates to a combination of cineole and amoxicillin for use in the treatment of an infectious pathology, preferably a bacterial infection, in an individual. The present combination may also comprise a ?-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to combat infections caused by bacteria that are resistant to antibiotics, preferably to antibiotics of the ?-lactamine family.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 16, 2024
    Assignee: ADVANCED SCIENTIFIC DEVELOPMENTS
    Inventors: Adnane Remmal, Ahmed Amine Akhmouch
  • Patent number: 11872217
    Abstract: Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R2a?, R2b?, R2c?, R3?, R4?, R5?, R6a?, R6b?, Y, Y?, and the subscripts m and n are as defined herein.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 16, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Viengkham Malathong, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11872218
    Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: January 16, 2024
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Gareth Winckle, Gregory T. Fieldson
  • Patent number: 11872219
    Abstract: The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: January 16, 2024
    Assignee: Centrexion Therapeutics Corporation
    Inventors: James N. Campbell, Barton Harley Manning
  • Patent number: 11872220
    Abstract: The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: January 16, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eric Frederik Eldering, Karoline Kielbassa, Ulrike Philippar, Andrew Steele, Marco Vincent Haselager, A. P. Kater
  • Patent number: 11872221
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 16, 2024
    Assignee: HUA Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Shuang Ren, Jiayi Zhang
  • Patent number: 11872222
    Abstract: This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: January 16, 2024
    Assignee: NeRRe Therapeutics Limited
    Inventors: Mike Trower, Stephen Pawsey, Mary Kerr
  • Patent number: 11872223
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: January 16, 2024
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng Li
  • Patent number: 11872224
    Abstract: The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: January 16, 2024
    Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co. (Beijing), Ltd.
    Inventors: Chi-Feng Yen, Fang-Wei Tien
  • Patent number: 11872225
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Patent number: 11872226
    Abstract: The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: January 16, 2024
    Assignee: MEDIBIOFARMA, S.L.
    Inventors: Julio Castro Palomino Laria, Juan Camacho Gómez, Rodolfo Rodríguez Iglesias, Irene Velilla Martínez
  • Patent number: 11872227
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: January 16, 2024
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Brian North, Steven Quayle
  • Patent number: 11872228
    Abstract: The present disclosure is a pharmaceutical composition for the prevention or treatment of sepsis containing a thiamine derivative or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of the present disclosure can be used for the prevention, alleviation, or treatment of sepsis by containing fursultiamine or allithiamine to inhibit the expressions of CD40, CD86, and TNF?.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: January 16, 2024
    Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL
    Inventors: In Kyu Lee, Eun Jung Choi, Chang Hyun Jeon, Tae-Hwan Kwon, Dong Ho Park
  • Patent number: 11872229
    Abstract: Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: January 16, 2024
    Assignee: Principia Biopharma Inc.
    Inventors: Abu J. Ferdous, Mohammad R. Masjedizadeh, Wu Lin
  • Patent number: 11872230
    Abstract: The present invention relates generally to a therapeutic protocol for treating a subject having cancer. Taught herein is a method of treating cancer or reducing the risk of recurrence of cancer in a subject following an anti-cancer therapy.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: January 16, 2024
    Assignee: Agency for Science, Technology and Research
    Inventors: Zhenxun Wang, Wai Leong Tam, Lian Yee Yip, Ying Swan Ho, Zhengwei Wu, Bing Lim
  • Patent number: 11872231
    Abstract: The disclosure provides a composition configured for oral use, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: January 16, 2024
    Assignee: Nicoventures Trading Limited
    Inventors: Christopher Keller, Ronald K. Hutchens, Thomas H. Poole, Nicolas von Cosmos, Anthony Richard Gerardi, Chris J. Grimes, Steven Lee Alderman, Darrell Eugene Holton, Jr.
  • Patent number: 11872232
    Abstract: Provided herein include caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. Also provided are methods for the production of caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. In some embodiments, disclosed compositions may provide consumers with increased alertness and wakefulness, while preventing side effects commonly associated with caffeinated drinks.
    Type: Grant
    Filed: April 12, 2023
    Date of Patent: January 16, 2024
    Assignee: RAREBIRD, INC.
    Inventors: Jeffrey Dietrich, Maddison Kylie Gurrola, Amanda Jacklyn Grace Sinrod, Edwin Yparraguirre Palang
  • Patent number: 11872233
    Abstract: Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: January 16, 2024
    Assignee: IC-MedTech Corp.
    Inventors: Sueli de Oliveira Silva Lautenschlager, Vania Cristina Desoti, Celso Vataru Nakamura, Valdecir Farias Ximenes
  • Patent number: 11872234
    Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: January 16, 2024
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
  • Patent number: 11872235
    Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one. Pharmaceutical compositions and the dosage forms of the bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters can be used to treat any condition associated with testosterone deficiency, including complete absence of endogenous testosterone in male or female subjects.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: January 16, 2024
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
  • Patent number: 11872236
    Abstract: Methods of treating presbyopia or cataract in a subject in need thereof are provided. The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecular weight aggregates of human ?-A-crystallin. Compositions containing certain compounds are believed to be also effective in the treatment of transthyretin (TTR)-associated amyloidosis and Parkinson's disease.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 16, 2024
    Assignee: CALASIA PHARMACEUTICALS, INC.
    Inventors: Surya Kanta De, Sridhar G. Prasad, Marshall Clarke Peterman, Bernard Collins
  • Patent number: 11872237
    Abstract: The present invention relates to a pharmaceutical composition comprising a sulfonamide as an inhibitor of Bcl-2/Bcl-xL, especially compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoromethyl sulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester or a pharmaceutically acceptable salt thereof and suitable excipients, preferably a pharmaceutical composition in the form of a lyophilized powder. The invention also relates to a method for preparing the pharmaceutical composition.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: January 16, 2024
    Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
    Inventors: Ming Guo, Yanqiong Lin, Zhenzhong Shao, Pengfei Cao
  • Patent number: 11872238
    Abstract: Use of a sialyllactose, or a nutritional composition comprising a sialyllactose, to enhance attention and/or to decrease impulsivity in a subject.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: January 16, 2024
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Jonas Hauser, Simone Macri
  • Patent number: 11872239
    Abstract: The present invention relates to a composition comprising an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides and one or more lipid moiety, wherein said one or more lipid moiety is covalently linked to said oligomeric compound either directly or via a spacer, and wherein preferably said oligomeric compound comprises from 5 to 40 monomer subunits, as well as pharmaceutical compositions thereof and their uses in the prevention or treatment of neuromuscular or musculoskeletal diseases such as Duchenne muscular dystrophy or Steinert disease.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: January 16, 2024
    Assignee: Synthena AG
    Inventors: Wolfgang Andreas Renner, Branislav Dugovic, Reto Bertolini
  • Patent number: 11872240
    Abstract: The present invention relates to antimicrobial formulations comprising Vitamin D as carrier loaded with an antibiotic. More specifically, the present invention relates to antimicrobial compositions comprising vitamin D as carrier loaded with an antibiotic for controlling infections and managing potentially infected wounds or infected wounds or treating infected implants used in orthopaedic surgery and various other conditions leading to healing of the wounds and avoidance of development of antibacterial resistance and avoiding complications related to the use of prolonged antibiotics by systemic route.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: January 16, 2024
    Inventors: Chander Shekhar, Khalid Khan, Shruti Kaushik
  • Patent number: 11872241
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 16, 2024
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • Patent number: 11872242
    Abstract: A method of treating an individual infected with COVID-19, the method comprising the steps of: providing an individual infected with COVID-19; and administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: January 16, 2024
    Inventor: Sabine Hazan
  • Patent number: 11872243
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: January 16, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
  • Patent number: 11872244
    Abstract: A method of treatment includes agitating a thixotropic oxidized cellulose solution; administering the agitated thixotropic oxidized cellulose solution to a target tissue site; and allowing the agitated thixotropic oxidized cellulose solution to gel at the target tissue site.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 16, 2024
    Assignee: Covidien LP
    Inventors: Rachit Ohri, Phillip D. Blaskovich, Min-Shyan Sheu, Petra Brockfeld
  • Patent number: 11872245
    Abstract: According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: January 16, 2024
    Assignee: TRIMPH IP PTY LIMITED
    Inventors: Ali Fathi, Fariba Dehghani
  • Patent number: 11872246
    Abstract: A nutritional supplement provides Vitamin E; Sophora flavescens extract; zinc sulfate; and a remainder of at least one of the following ingredients: grape seed extract; boswellia extract; micronized Resveratrol; Vitamin B6; black pepper; magnolia powder; poplar powder; willow bark powder; methyl sulfano methane; chia; Vitamin C; Pine powder; Curcumin; Oregano; Ginger; Orange peel; and Meadow sweet. The supplement can be used to reduce joint inflammation, reduce stiffness, reduce lameness, improve flexion, and improve amount of movement and mobility by supporting joint health.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: January 16, 2024
    Inventor: Frank Kelly Reilly, III
  • Patent number: 11872247
    Abstract: The present invention relates to the use of a combination of a wound-rinsing solution and cold atmospheric plasma for treating wounds. The present invention further relates to a method for treating wounds, comprising rinsing the wound with a wound solution and treating the wound with cold atmospheric plasma.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: January 16, 2024
    Assignee: Westfaelische Wilhelms-Universitaet Muenster
    Inventor: Heinrich Rotering